Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved. But now, an initiative spearheaded by Takeda is starting to shift the dial.